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Abstract  
Introduction 
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Acute Kidney Injury (AKI) prevalence in the UK is estimated to be about 20% of all emergency admissions. 
Complications of AKI have a huge impact on healthcare costs.  Most studies that have looked at the 
economic costs of AKI have used macro level costing by using national tariffs and applying this to 
Hospital Episode Statistics.   
Methods 
The Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) study was a pilot study testing 
the provision of early specialist advice to improve outcomes for patients with AKI.  As part of this 
prospective study, we undertook a health economics sub-study which involved micro costing to help 
more accurately define the total cost per patient.   
Results 
We found that the total cost of providing an AKI alert system and an outreach service (intervention 
group) was lower than current practice (control group) for patients with AKI.  Overall an episode of AKI 
requiring inpatient care costs about £5,000 over 12 months, somewhat higher than previous UK 
estimates.  Even though it is feasible to collect the required complex dataset needed to conduct a health 
economics analysis of an outreach service, significant amount of time and resources need to be 
dedicated.   
Conclusion 
We have shown that it is possible to demonstrate a clearer, more detailed picture of the prolonged 
economic costs of AKI for a healthcare system, as part of a sub-study of a larger trial.  A larger scale 
randomised controlled trial of AKI outreach is needed with a prospective full economic evaluation 
conducted alongside the trial.  
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BACKGROUND 
Acute Kidney Injury (AKI) prevalence in the UK is estimated to be >20% of emergency admissions(1) and 
complications of AKI are now well established as having a huge impact on healthcare costs.  The cost 
implications for the National Health Service (NHS) include increased hospital stay, intensive care unit 
(ICU) admissions, post-discharge costs, and also an increased risk of longer-term health problems.  
Likewise, the cost of dialysis also adds to the economic burden.  In 2005, Chertow and colleagues 
concluded a robust association between AKI and both increased hospital costs and length of hospital 
stay.(2)  The more severe the case of AKI, the higher the impact.   
 
Prevention of approximately 30% of AKI cases was estimated to save the NHS between £130m to £186m 
per year.(3)  Obviously, extended hospital stay will have an undesirable effect.  One audit found that 
preventing a modest 10% of AKI cases could save the hospital 3,000 bed days per year.(4)  The literature 
has tended to focus on the cost of different renal replacement modalities in the highly selected minority 
of patients that require these therapies.(5, 6)   
 
There have been studies indirectly estimating the costs of relatively unselected AKI patients admitted to 
hospital.  Fischer et al studied over 2,000 patients admitted to Massachusetts Hospitals with 
uncomplicated AKI (not requiring critical care) at the turn of the millennium, identified by ICD-9.(7)  
Direct hospital costs were estimated from hospital charges for the AKI admission. 10% of patients 
required dialysis, which increased costs by 63%.  Median direct hospital costs were $2,600 per 
admission.(7)  Kolhe et al in the UK estimated the cost of AKI in 576 inpatients coded by ICD-10 as having 
AKI in their centre, out of a total of about 140,000 admissions in 2008.(8)  About 5% of patients needed 
renal replacement therapy.  Using an averaging and relative value methodology to predict AKI costs, they 
estimated a cost of about £3,750 per admission.  The total annual cost of AKI admissions to the English 
NHS was estimated to be about £3 billion.  Studies based on coded AKI diagnoses have a potential 
weakness in that coding is known to miss many patients with AKI.(9, 10) 
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A recent study looked into the economic impact of AKI to the NHS using data which was recorded in the 
Hospital Episodes Statistics (HES).(3)  Kerr et al estimated the cost of AKI in the English NHS in 2010 using 
HES data in patients admitted and coded to an AKI related Healthcare Resource Group (HRG) (HRG code: 
LA07).(3)  For these admissions, the authors attributed the entire cost of the admission to AKI, and used 
the tariff price to estimate the unit cost.  Using the national tariff (costing) for this HRG, they found that 
over 23,000 admissions had cost about £75 million, a cost of £3,250 per patient.  This cost did not 
include critical care, post-discharge care or excess bed days in patients with AKI that was coded to other 
HRGs, resulting in an under-recording of AKI resource usage in their estimates.  A Markov model was 
used: estimated the annual cost associated with AKI-related inpatient care in England was £1.02 billion 
and the lifetime cost of post-discharge care for people who have had AKI as inpatients in 2010–11 was 
estimated at £179 million.(3)   
 
The Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) project is a pilot study of the 
use of the Outreach service for patients with AKI.(11)  We conducted a health economics sub-study, 
which aimed to more accurately define the total cost per patient, with or without the use of an AKI 
Outreach team, over 12 months from an AKI alert.  This paper shows the feasibility of conducting a cost-
effectiveness analysis of the AKI Outreach team versus standard care, and is the first to conduct a direct 
micro-costing of AKI for each individual patient.    
 
METHODS 
The AKORDD study took place in two hospitals: Heartlands Hospital (intervention) and Good Hope 
Hospital (control).  The study used a Before and After design, piloting the Outreach service to patients 
with AKI.  For the Before study phase (2 months), both hospitals received standard care and for the After 
study phase (5 months), Good Hope hospital continued to receive standard care, whereas, Heartlands 
hospital received the intervention (Outreach via telephone).  Patients were recruited once they had an 
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electronic alert indicating that they have AKI.  The Outreach service offered rapid assessment, treatment 
and advice for patients who develop AKI to reduce their risk of death, dialysis and other complications.  
The team functioned during working hours, 5 days/week, offering advice to clinicians looking after AKI 
patients.  Depending on the stage of AKI the level of intervention from the Outreach team differed.  For 
example, for relatively mild AKI (stage 1) there was telephone call with a member of the team, whilst if 
AKI was quite serious (stage 3) there was a telephone call with a consultant plus a consultant visit.  The 
trial, as a pilot study, was powered to estimate the rate of the combined endpoint (any of these: AKI 
stage deterioration, dialysis, or death) for a future cluster randomised trial.  The health economic sub-
study was designed to test methods of economic assessment in AKI.  Overall study design is detailed 
elsewhere.(11)   
 
Recruitment 
For the health economics sub-study we aimed to recruit a sample of 50 patients during the After phase: 
25 patients from each hospital from the main study population and data was collected during the 12-
month period starting from recruitment.  Two one-week recruitment windows (in July and October 2015) 
were opened simultaneously at each hospital.  The actual starting point for each patient for health 
economics analysis was the time of the AKI alert, excluding costs prior to the onset of AKI.  Only patients 
admitted to the control or intervention hospital were recruited; patients with AKI who remained in the 
community were not eligible for recruitment.  The health economics sub-study was approved by the 
Research Ethics Committee of the National Research Ethics Service in 2014 (NRES Committee East 
Midlands - Nottingham 1, reference 14/EM/0184).  A Consort diagram for the After phase is published 
elsewhere.(12) 
 
Resource use data collection and unit costs 
The cost analysis adopted an NHS and personal social services perspective.  Resource use items which 
were directly linked to the index AKI episode and its sequela/complications were costed over the 12 
months of follow-up for each patient recruited.  Thus an admission or outpatient appointment for an 
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unrelated condition (such as a comorbidity exacerbation or surgical procedure) were excluded from the 
analysis.  These admissions and visits were attributed unblinded by the chief investigator to keep the 
workload manageable.  We collected resource use and unit cost data for the following items:  
• AKI Outreach team which included costs of implementing and running the service including staff 
costs.  The core Outreach team consisted of an experienced renal consultant (MT), a renal 
research fellow (TA) and a critical care nurse trained in AKI.  The team was responsible for 
delivering the interventions, with or without ward visits, triggered by the AKI alert; 
• The index hospital stay from the time of the AKI alert (see above) to discharge, including any 
intensive care unit admissions, general ward admissions and consultant ward rounds conducted 
by the “home team” (the team primarily responsible for the patients care at that time); 
• Subsequent related hospital stay(s) – costed as for the index hospital stay 
• Subsequent related outpatient clinic visits – consultant or nurse-led, first or follow-up clinics;  
• Dialysis – haemodialysis or peritoneal dialysis (PD - including assisted automated PD);  
• All tests or investigations, including all blood or other laboratory tests, all imaging, endoscopies, 
and other diagnostic procedures (including electrocardiograms);  
• Supportive procedures including intravenous cannulation, urinary catheterisation and blood 
transfusion; 
• Intravenous fluids; and  
• Medications whilst in hospital and supplied by the hospital when patients were discharged (28 
days provided).  Inpatient medications usage included recording all administered doses of a given 
drug at a given dose, excluding all doses prescribed but not administered, and separately 
recording any doses at a new or changed dose regime.  This allowed calculation of the exact cost 
of a specified number of doses of a drug at a given dosage.  
 
For most of the resource use items listed above the data was available via electronic patient records and 
the pathology laboratory system.  Prescribing data was taken from the JAC electronic prescribing 
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system (JAC Computer Services Ltd).  We also consulted the renal information technology system 
(Proton, Clinical Computing Ltd) for data regarding dialysis.  Where necessary we also reviewed the 
paper notes to extract any additional information.  These were reviewed chiefly for information from 
departments such as emergency medicine and critical care, which do not use electronic patient records.  
 
In addition to hospital resource use data, we also collected data via a patient self-reported 
questionnaire.  This was a practical means of collecting non-secondary care data which included general 
practitioner visits at surgery, home or via telephone, practice nurse visits at surgery, and any community 
health services such as a community nurse, allied health professional or walk-in centre visits.  In addition, 
this questionnaire also included any non-prescribed (over the counter) medications which the patients 
may have also purchased.  These questionnaires were sent to the patients by post for self-completion or 
they were filled in by the research fellow or nurse asking the questions over the telephone.  For each 
patient, four questionnaires were administered at the following time points: 3, 6, 9 and 12 months to 
take into account resource use for the 3 months prior to the questionnaire date.  Thus the 3 month 
questionnaires asked about resource use incurred from the time of the alert (baseline) to 3 months.  
 
Unit costs for the key resource use items were based on the 2015/2016 financial year (see Table 1) and 
are presented in pounds sterling.  Staff costs were obtained from the Unit Costs of Health and Social Care 
(13, 14) and the Pay and Conditions Circular(15); inpatient stays, outpatient visits and dialysis costs from 
the NHS reference costs(16); costs of medications and intravenous fluids from the British National 
Formulary (17); tests and investigations from published sources such as NHS reference costs, NHS Trusts 
websites and National Institute of Health Care and Excellence (NICE) guidelines.(16, 18-20)  The tests and 
investigations costs are presented in Supplementary Table 1.  The unit costs were then attached to each 
resource item to calculate a total cost per patient.   
 
Outcome data collection 
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Health-related quality of life was assessed using standardised EQ-5D-5L questionnaire which consists of 
two parts: the descriptive part and the visual analogue scale (VAS).  The descriptive system compromises 
5 attributes of health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression).(21)  
Each attribute has five levels (no; slight; moderate; severe; extreme problems/unable to), generating a 
total of 3,125 possible health states.  Preferences for the scoring function were measured using the 
mapping algorithm for the crosswalk value set from EQ-5D-5L to EQ-5D-3L.(22)  The scores lie on a value 
scale from 0.0 (dead) to 1.0 (perfect health).  The EQ-5D VAS records the respondents’ self-rated health 
status on a 0-100 scale where 0 is the worst state you can imagine and 100 is the best state you can 
imagine.  The EQ-5D-5L questionnaire was administered to patients in the same sitting as resource use 
questionnaire.  The EQ-5D-5L was administered at baseline as soon as the patient was well enough to 
respond to questions after the alert.  The EQ-5D-5L results were used to calculate utility scores for each 
time period and generate quality-adjusted life years (QALYs).  QALYs simply measure the area under the 
curve where the amount of time (e.g. one year) spent in a health state(s) on the horizontal axis is 
weighted by the utility score(s) given to the health state(s) on the vertical axis.  QALYs were calculated by 
the simply calculating the area under their utility curve, assuming a linear change in utility from baseline 
to one year. 
 
Missing data 
Multiple imputation was used to estimate the missing EQ-5D data and resource use data as reported in 
the questionnaires.  Multiple imputation is a Monte Carlo simulation technique where each missing data 
case is replaced by a set of plausible estimates.  The technique uses information on the relationship 
between variables as part of the estimation process to produce overall mean estimates for the missing 
data.  Information on the patients age, sex, residence, ethnicity, AKI alert stage and baseline EQ-5D-5L 
scores, where included to predict missing values.(23, 24)  Missing data was imputed for the EQ-5D-5L for 
each attribute for each level that was missing and for non-secondary care resource use data for each 
resource use that was missing.  The missing data was imputed using the statistical packages NORM.(25) 
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Data presentation and statistical analysis 
Microsoft Excel® and Stata version 14(26) were used.  Results are presented for costs, utility scores and 
QALYs for all cases with and without imputed data for the two hospitals.  Statistical tests (t-test and F-
test based on the bootstrap method – see below) were used to explore the difference in costs and utility 
values between the two hospitals.  All tests were two sided and a p value of ≤ 0.05 was considered to be 
statistically significant.   
 
As the distributions of cost data were skewed, bias adjusted non-parametric bootstrapping were 
performed with 10,000 iterations in order to generate confidence limits around the mean values.  
Bootstrapping is a simulation technique that takes repeated samples of data, with replacement and, in 
the absence of any other data from the population, gives a guide to its distribution.(27)   
 
RESULTS 
In total, 48 patients consented and were recruited for the health economics sub-study: 20 patients for 
the Intervention Hospital and 28 patients for the Control Hospital.  At the intervention hospital, 2 were 
too sick for consent, and 3 declined.  At the control hospital, 11 were too sick to provide consent, 1 died 
before approach, 6 declined involvement in the sub-study.  Table 2 summarises the baseline 
characteristics.  The mean age was similar for both hospitals; there were slightly more males in the 
intervention hospital (p = 0.065); majority of patients for the intervention hospital resided in 
independent homes; and the majority of patients had a mild impairment of kidney function, which was 
not statistically significant between the two hospitals (p = 0.322).  The intervention hospital at baseline 
had slightly better EQ-5D-5L utility and VAS scores than the control hospital, although this was not 
statistically significant. 
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Eleven patients in Heartlands hospital and 22 patients in Good Hope hospital completed the 3 to 12 
months questionnaires.  Only 4 patients in the intervention hospital and 9 patients in the control hospital 
completed questionnaires for all time points (see Table 3 for more information).   
 
Table 4 shows the results of the EQ-5D-5L utility scores (tariffs).  The intervention hospital had slightly 
better utility scores than the control hospital for all time periods for the completed cases (with no 
imputed data) and these differences were not statistically significant.  Over time (from baseline to 12 
months) these differences in utility scores were statistically significant for all cases which included the 
imputed data (F = 8.63, p = 0.001) and for completed cases only with no imputed data (F = 6.70, p < 
0.001). 
 
Table 5 shows the overall QALY gain for the 12 month period.  For all cases, which included imputed data 
there was an overall QALY gain of 0.066 for the intervention hospital compared to the control hospital, 
although this difference was not statistically significant (p = 0.332) and for completed cases only which 
included no imputed data there was an overall QALY gain of 0.018 for the intervention hospital 
compared to the control hospital, again this difference was not statistically significant (p = 0.906). 
 
Table 6 shows the frequency of some of the key resource use items including medications, tests and 
investigations.  Overall, patients in the intervention group had a lower mean length of stay in the general 
ward, although not statistically significantly so, compared to the control group (8.6 vs. 9.9 days, p = 
0.712).  The intervention group also had fewer consultant ward rounds which were conducted by the 
home team compared to the control group (3.2 vs. 4.5 rounds, p = 0.340).   
 
There were slightly more GP visits to the surgery by the intervention group than the control group (9.09 
vs. 6.59, p = 0.058), see Table 7.  Whereas the control group had more contacts with other health 
professionals, none of these resources where statistically significantly different between the two groups. 
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The total mean NHS costs of the initial AKI episode and any additional costs relating to the initial index 
episode during the 12 month period was £1,094 lower for the intervention group than the control group, 
although this difference was not statistically significant (p = 0.647).  This was also reflected in the wider 
95% confidence interval for the control group compared with the intervention group.  One patient within 
the control group was driving the cost as they were the only person to have multiple ward admissions 
which was linked to the original AKI episode.  Furthermore, this person also had both inpatient 
heaomodialysis sessions and automated peritoneal dialysis which contributed to the higher cost for the 
control group.  Removing this patient from this group, the mean (SD) total NHS costs falls to £5,232 
(£5,194) and 95% confidence intervals were also narrower £3,273 to £7,191 (t test = 0.273, p = 0.786).   
 
Patients costs as outlined earlier in the methods section included patients recalling visits to the GP 
surgery or with a community nurse, or any over counter medications was slightly higher for the control 
group than the intervention group (£359 vs. £248, p = 0.150) (see Table 8). 
 
DISCUSSION  
Although this pilot study showed that the total cost of providing an AKI alert system and an outreach 
service (intervention group) was lower than current practice (control group) for patients with AKI, the 
results from this study need to be interpreted with caution due to a number of inherent uncertainties, 
most notably the small sample size.  To the best of our knowledge, this is the first study that has 
conducted a prospective micro-level costing of NHS resources for patients with AKI, where patient care 
relating to that index episode has been followed up for 12 months and the resource use appropriately 
costed.  As well as the direct micro-costing, our strengths include costing only from AKI onset, and 
inclusion of related post AKI care involving outpatient care or further admissions.  To our knowledge our 
work is also the first to demonstrate that AKI patients do incur significant personal costs, in a group 
which is typically elderly and disadvantaged.  Overall, the costs calculated by our methods are higher 
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than one recent UK estimate(8), suggesting that the economic impact of AKI is even greater than 
previously thought. 
 
However, there are limitations with this pilot study.  Consenting of sick patients with AKI to take part in a 
sub-study is challenging at a time when they are acutely unwell.  More severe AKI will be under-
represented.  Even after recovery they often have chronic ill health, which made it difficult to obtain 
follow up EQ-5D and resource use questionnaires.  Resource use and costs provided on behalf of the NHS 
were conservatively estimated; that is, only the resource use and costs as a direct consequence of the 
initial AKI episode and any further visits related to the initial AKI episode have been included.  Any 
further inpatient admissions, outpatients visits, tests/investigations or medications within that 12 month 
period after the AKI alert which were not directly related to that initial AKI episode were excluded.  We 
excluded any resource use/costs that we couldn’t be sure that they were directly related to the initial AKI 
episode, as it may have been due to some other underlying cause.  Even so, our documentation of the 
costs of AKI will be more complete than those analyses that included only direct hospital costs. The high 
cost in the control group was due to one patient having multiple admissions which were linked to the 
original AKI episode and also this patient was on dialysis.  As expected in any costing study for AKI, cost 
data will be skewed by a small proportion of patients with complications. 
 
Only the time of the AKI outreach team was included in the costing.  The cost of the alert system was not 
added to the costs, as this system was already in place.  If we had included community patients into the 
health economics analysis then the cost of the alert system would have to be included.  For this sub-
study no patients from the community were recruited due to research team and time limitations. 
 
Even though the EQ-5D results for the intervention group were slightly, although not statistically 
significantly better compared to the control group, this is most likely because the EQ-5D is based on a 
biased sample.  That is, the patients recruited into the health economics sub-study were more likely to 
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be younger and they were not as sick; about two-thirds of the patients in the sub-study had a lower 
grade of AKI.   
 
We can’t be sure that patient costs have been accurately recorded.  For example, patients who may be 
slightly older and not as well, may find it difficult to recall resource use.  For example, the number of 
visits to the GP surgery for the previous three months and whether this visit was linked with the index 
AKI episode.  Accurate collection of primary care data is needed and this needs to be linked up with GP 
and social care records. 
 
We have not calculated an incremental cost-effectiveness ratio due to the very small numbers who 
completed the EQ-5D questionnaire for all relevant time points.  Any ratio estimated would be with great 
uncertainty and the confidence intervals would have been huge. 
 
CONCLUSION 
This study has shown that it is feasible to collect the complex data needed to conduct a health 
economics analysis of the use of an alert and an Outreach service for patients with AKI in the hospital; 
however, significant research time would need to be dedicated in order for this to be undertaken.  
Future considerations also need to include the scale of the outreach service i.e. how many hospitals, 
availability of AKI staff and an outreach team with the right skill mix.  We advocate the use of the 
methodology in this paper by subsampling, with researchers administering questionnaires both in 
hospital and community; and have blinded assessment of AKI related events.  This would give a better 
picture of the whole economic impact compared with just estimation of the direct hospital costs.  Large 
scale AKI trials requiring health economic analysis should consider micro-costing in a subsample, for 
example in biomarker trials.  This study can help any future definitive multi-centre randomised 
controlled study of AKI outreach in planning the full prospective economic evaluation.  Any future 
interventions for AKI will help target procedures which are needed for patients and also help in reducing 
inpatient admissions.  
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Table 1: Key resource use items and unit costs 
Resource use item and mean time (in minutes) Cost (£) Source 
AKI team 
- Renal consultant (60.0) 
- Renal research fellow (60.0) 
- Critical care nurse (60.0) 
 
£135.59 
£59.38 
£46.47 
 
(13-15)  
(13-15)  
(13-15)  
General practitioner (GP) costs 
- GP at surgery (9.2) 
- GP at home (11.4) 
- GP on telephone (7.1) 
- Practice nurse at surgery (13.0) 
Community costs 
- Community nurse (17.5) 
- Community allied health professional (30.0) 
- Walk-in-centre (13.2) 
 
£36.00 
£45.00 
£28.00 
£9.32 
 
£14.58 
£20.00 
£38.87 
 
(13, 14) 
(13, 14) 
(13, 14) 
(13, 14) 
 
(13, 14) 
(13, 14) 
(13, 14) 
Bed-day costs 
- General ward (non-elective AKI without interventions)* 
- High dependency unit (requiring support for at least 1 organ) 
Clinic visits 
- Consultant-led first clinic 
- Consultant-led follow-up clinic 
 
£400.72 
£671.00 
 
£193.01 
£153.01 
 
(16) 
(16) 
 
(16) 
(16) 
Dialysis costs 
Haemodialysis for AKI (1 session approx. 4 hours) 
Assisted automated peritoneal dialysis (1 a day) 
 
£153.00 
£49.55 
 
(16) 
Heartlands Hospital 
* General ward cost was based on a non-elective stay without interventions to avoid double counting as interventions were 
costed separately 
 
Table 2: Baseline characteristics 
 Heartlands 
Hospital (n = 20) 
Good Hope 
Hospital (n = 28) 
Statistical test 
Mean age in years (SD) 65.0 (18.9) 66.5 (12.9) t = 0.319, p = 0.751 
Sex: Male (%) 14 (70.0%) 12 (42.9%)  χ2 = 3.461, p = 0.063 
Ethnicity (%) 
British 
Pakistani 
African 
Other 
 
17 (85.0%) 
3 (15.0%) 
0 (0.0%) 
0 (0.0%) 
 
24 (85.7%) 
1 (3.6%) 
1 (3.6%) 
2 (7.1%) 
 
Fisher’s Exact test = 
p = 0.329 
Residence  
Independent home 
Nursing home 
 
19 (95.0%) 
1 (5.0%) 
 
28 (100.0%) 
0 (0.0%) 
χ2 = 3.972, p = 0.264 
AKI alert stage – impairment 
of kidney function 
1. Mild 
2. Moderate 
3. Severe 
 
 
14 (70.0%) 
3 (15.0%) 
3 (15.0%) 
 
 
19 (67.9%) 
8 (28.6%) 
1 (3.6%) 
 
 
Fisher’s Exact test = 
p = 0.322 
EQ-5D-5L Mean (SD) 
Utility score 
VAS 
 
0.473 (0.299) 
49.25 (21.84) 
 
0.293 (0.402) 
44.60 (20.95) 
 
t =-1.69, p = 0.100 
t = -0.738, p = 0.464 
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Table 3: EQ-5D and resource use questionnaire completion 
Questionnaire completion Heartlands Hospital Good Hope Hospital 
Expected completion rates 
Baseline only  
Baseline – 12 months 
N = 20 
9 (45.0%) 
11 (55.0%) 
N = 28 
6 (27.3%) 
22 (78.6%) 
Actual completion rates 
Baseline 
3 months 
6 months 
9 months 
12 months 
Baseline – 12 months 
N = 11 
11 (100.0%) 
11 (100.0%) 
7 (63.6%) 
5 (45.5%) 
7 (63.6%) 
4 (36.4%) 
N = 22 
22 (100.0%) 
18 (81.8%) 
13 (59.1%) 
14 (63.6%) 
15 (68.2%) 
9 (45.5%) 
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Table 4: EQ-5D-5L utility scores (tariffs)  
 Heartlands Hospital Good Hope Hospital Test Heartlands Hospital Good Hope Hospital Test 
All cases (including cases with imputed data) Complete cases only (no imputed data) 
Baseline 
N 
Mean (SD) 
Median  
Interquartile range 
 
20 
0.473 (0.299) 
0.556 
0.305 to 0.666 
 
28 
0.293 (0.402) 
0.325 
-0.043 to 0.671 
 
t =-1.69, 
p = 0.100 
 
 
20 
0.473 (0.299) 
0.556 
0.305 to 0.666 
 
28 
0.293 (0.402) 
0.325 
-0.043 to 0.671 
 
t =-1.69, 
p = 0.100 
 
3 months 
N 
Mean (SD) 
Median  
Interquartile range 
 
11 
0.706 (0.334) 
0.848 
0.404 to 1.000 
 
22 
0.590 (0.240) 
0.570 
0.491 to 0.767 
 
t = -1.14, 
p = 0.259 
 
11 
0.706 (0.334) 
0.848 
0.404 to 1.000 
 
18 
0.594 (0.267) 
0.561 
0.381 to 0.813 
 
t =-0.999, 
p = 0.327 
 
6 months 
N 
Mean (SD) 
Median  
Interquartile range 
 
11 
0.660 (0.257) 
0.648 
0.567 to 0.837 
 
22 
0.660 (0.215) 
0.657 
0.585 to 0.836 
 
t = 0.00, 
p = 0.997 
 
7 
0.638 (0.332) 
0.740 
0.404 to 0.879 
 
13 
0.617 (0.235) 
0.541 
0.491 to 0.813 
 
t =-0.18, 
p = 0.861 
 
9 months 
N 
Mean (SD) 
Median  
Interquartile range 
 
11 
0.639 (0.186) 
0.580 
0.548 to 0.648 
 
22 
0.641 (0.220) 
0.679 
0.555 to 0.739 
 
t = 0.02, 
p = 0.982 
 
5 
0.706 (0.273) 
0.555 
0.548 to 1.000 
 
14 
0.659 (0.274) 
0.723 
0.516 to 0.850 
 
t =-0.33, 
p = 0.744 
 
12 months 
N 
Mean (SD) 
Median  
Interquartile range 
 
11 
0.743 (0.216) 
0.716 
0.654 to 1.000 
 
22 
0.663 (0.234) 
0.679 
0.567 to 0.819 
 
t = -0.95, 
p = 0.351 
 
 
7 
0.797 (0.259) 
0.796 
0.716 to 1.000 
 
15 
0.670 (0.284) 
0.698 
0.499 to 0.877 
 
t =-1.00, 
p = 0.328 
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Table 5: Quality-adjusted life year (QALYs) scores  
 Heartlands Hospital Good Hope Hospital Test Heartlands Hospital Good Hope Hospital Test 
All cases (including cases with imputed data) Complete cases only (no imputed data) 
N 
Mean (SD) 
Median  
Interquartile range 
11 
0.666 (0.181) 
0.723 
0.469 to 0.818 
22 
0.600 (0.182) 
0.631 
0.454 to 0.751 
 
t = -0.98, 
p = 0.332 
4 
0.649 (0.262) 
0.670 
0.424 to 0.874 
9 
0.631 (0.246) 
0.719 
0.441 to 0.808 
 
t = -0.12, 
p = 0.906 
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Table 6: Frequency of key resources in hospital 
 Heartlands 
Hospital 
(n = 20) 
Good Hope 
Hospital  
(n = 28) 
Statistical test 
General admission ward stay in days 
Mean (SD) 
Median 
Interquartile range 
Range 
 
8.6 (10.6) 
6.5 
4.5 to 8.0 
2.0 to 52.0 
 
9.9 (11.1) 
6.5 
3.5 to 11.5 
2.0 to 45.0 
 
t = -0.370, p = 0.712 
Consultant ward rounds 
Mean (SD) 
Median 
Interquartile range 
 
3.2 (3.1) 
2.5 
2.0 to 4.0 
 
4.5 (5.6) 
3.0 
1.5 to 5.0 
 
t = -0.964, p = 0.340 
Medications in hospital (6 most frequent) 
N (%) 
Co-amoxiclav 
Cyclizine 
Enoxaparin 
Furosemide 
Omeprazole 
Paracetamol 
 
 
12 (60.0%) 
5 (25.0%) 
15 (75.0%) 
4 (20.0%) 
9 (46.0%) 
17 (85.0%) 
 
 
11 (39.3%) 
12 (42.9%) 
27 (96.4%) 
13 (46.4%) 
14 (50.0%) 
28 (100.0%) 
 
 
χ2 = 4.095, p = 0.536 
Medications on discharge (5 most frequent) 
N (%) 
Omeprazole 
Paracetamol 
Prednisolone 
Salbutamol 
Simvastatin 
 
 
7 (35.0%) 
7 (35.0%) 
0 (0.0%) 
1 (5.0%) 
3 (15.0%) 
 
 
10 (35.7%) 
14 (50.0%) 
17 (60.7%) 
12 (42.9%) 
8 (28.6%) 
 
 
χ2 = 11.422, p = 0.022 
Investigations 
Mean (SD) 
Full blood count  
Urea and electrolytes 
Liver function tests 
Prothrombin time, prothrombin 
concentration, international normalised ratio 
C reactive protein 
Bone profile 
Blood culture 
Urine culture and sensitivity 
Arterial blood gas 
Immune profile 
Erythrocyte sedimentation rate 
Creatinine kinase 
Plasma or serum glucose 
Tests 
Mean (SD) 
Chest x-ray 
Renal ultrasound 
Peripheral venous cannulation 
Catheter 
ECG 
 
 
5.0 (4.2) 
6.0 (4.2) 
2.0 (2.9) 
1.3 (1.3) 
 
2.1 (4.1) 
1.0 (1.3) 
0.5 (0.8) 
0.7 (1.2) 
0.4 (0.7) 
0.3 (0.4) 
0.1 (0.3) 
0.2 (0.5) 
0.1 (0.3) 
 
 
0.4 (0.6) 
0.5 (0.8) 
1.4 (1.2) 
0.5 (0.8) 
0.1 (0.2) 
 
 
5.8 (7.6) 
6.3 (8.2) 
2.1 (4.7) 
1.8 (2.8) 
 
1.9 (3.3) 
1.4 (4.1) 
0.6 (0.8) 
0.7 (0.9) 
0.1 (0.4) 
0.6 (1.3) 
0.1 (0.3) 
0.2 (0.4) 
0.1 (0.4) 
 
 
0.8 (1.4) 
0.3 (0.5) 
1.6 (1.9) 
0.3 (1.0) 
0.1 (0.8) 
 
 
t = -0.421, p = 0.676 
t = -0.150, p = 0.882 
t = -0.090, p = 0.929 
t = -0.731, p = 0.469 
 
t = 0.162, p = 0.872 
t = -0.372, p = 0.711 
t = -0.293, p = 0.771 
t = 0.073, p = 0.942 
t = 1.700, p = 0.096 
t = -1.027, p = 0.310 
t = 0.346, p = 0.731 
t = -0.225, p = 0.823 
t = -0.434, p = 0.666 
 
 
t = -1.294, p = 0.202 
t = 0.793, p = 0.432 
t = -0.519, p = 0.606 
t = 0.489, p = 0.627 
t = -0.531, p = 0.598 
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Table 7: Frequency of key resources from the patient self-reported questionnaires (including imputed 
data) 
Mean (SD) Heartlands 
Hospital 
(n = 11) 
Good Hope 
Hospital  
(n = 22) 
Statistical test 
GP at surgery 
GP at home 
GP via telephone 
Nurse at surgery 
Community nurse 
Community allied health professional 
9.09 (3.11) 
0.64 (0.67) 
1.27 (1.19) 
2.27 (1.56) 
1.82 (2.27) 
0.00 (0.00) 
6.59 (3.58) 
1.59 (3.59) 
1.77 (1.97) 
3.36 (2.56) 
2.05 (3.66) 
1.32 (3.29) 
t = -1.970, p = 0.058 
t = 0.867, p = 0.393  
t = 0.769, p = 0.448 
t = 1.295, p = 0.205 
t = 0.188, p = 0.852 
t =1.320, p = 0.197 
 
There were slightly more GP visits to the surgery by the intervention group than the control group (9.09 
vs. 6.59, p = 0.058), see Table 8.  Whereas the control group had more contacts with other health 
professionals, none of these resources where statistically significantly different between the two groups. 
 
Table 8: Bootstrapped total NHS and patient costs 
 Heartlands Hospital 
(n = 20) 
Good Hope Hospital  
(n = 28) 
Statistical test 
Total NHS costs 
Mean (SD) 
95% confidence interval 
 
£5,661 (£5,223) 
£3,371 to £7,950 
 
£6,755 (£9,368) 
£3,285 to £10,225 
 
t = -0.467, p = 0.647 
Total patient costs 
Mean (SD) 
95% confidence interval 
 
£248 (£233) 
£147 to £349 
 
£359 (£265) 
£260 to £458 
 
t = -1.465, p = 0.150 
 
 
 
Supplementary Material 
Supplementary Table 1:  detailing test and investigations costs. Supplementary information is available at 
KI Reports website.   
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